EGFR and non-small cell lung carcinoma: For this reason, among the 22 NSCLC patients from the ID-MUT study with EGFR mutations treated by EGFR-TKI, 12 NSCLC patients harboring EGFR mutations received treatment following EGFR genotyping by the NGS method, while the other 10 patients with NSCLC and EGFR mutations received EGFR-TKI treatment according EGFR genotyping by the IdyllaTM system (i.e., before the EGFR genotyping result by NGS was known), allowing the evaluation of the contribution of the IdyllaTM system to improving the therapeutic care of patients with NSCLC by early screening of EGFR mutations (Table 2).